BCL2 G101V Solvent-Front Mutation and Venetoclax Resistance

Venetoclax has transformed the treatment of chronic lymphocytic leukemia (CLL) and other BCL2-dependent hematologic malignancies, but acquired resistance limits durability. Among the most frequently reported resistance mutations is BCL2 G101V, a solvent-front substitution in the BH3-binding groove that directly disrupts venetoclax engagement while preserving anti-apoptotic function.

BCL2 and the BH3 Mimetic Mechanism

BCL2 is an anti-apoptotic protein that binds pro-apoptotic BH3-only proteins such as BIM, PUMA, and BAD through a hydrophobic groove on its surface. This sequestration prevents the activation of BAX and BAK, blocking mitochondrial outer membrane permeabilization and cell death. Venetoclax is a selective BH3 mimetic that binds the same hydrophobic groove with nanomolar affinity, displacing pro-apoptotic proteins and restoring apoptosis in malignant cells overexpressing BCL2.

The BH3 groove is a deep cleft formed by the BCL2 alpha-helical bundle, with four critical pockets designated P1 through P4. Venetoclax occupies these pockets through a combination of hydrophobic contacts, hydrogen bonds, and van der Waals interactions. Residues lining the groove—including glycine 101—are essential for accommodating the inhibitor's bulky scaffold.

G101V: A Solvent-Front Mutation That Blocks Venetoclax

Glycine 101 is located at the solvent-front edge of the P2 pocket within the BH3 groove. This position is structurally constrained: glycine's lack of a side chain provides the spatial tolerance required for venetoclax's indole-oxadiazole moiety to fit snugly into the binding site. Substitution to valine introduces a branched aliphatic side chain that projects into the groove, creating steric clash with the inhibitor.

Clinical studies in relapsed CLL patients have identified BCL2 G101V as a recurrent acquired mutation following venetoclax therapy. Biochemical assays demonstrate that G101V reduces venetoclax binding affinity by 10- to 100-fold, while native BH3 peptide binding is less affected. This selectivity allows the mutant protein to retain anti-apoptotic function against endogenous BH3 partners while escaping inhibition by the drug.

Importantly, G101V is classified as a solvent-front mutation, not a gatekeeper mutation. Gatekeeper residues control access to a deeper hydrophobic pocket in kinases and some other targets, whereas solvent-front mutations like G101V alter the geometry of the binding surface itself without a traditional gate mechanism. This distinction is critical for understanding resistance patterns and designing next-generation inhibitors.

Structural Basis of Resistance

Crystal structures of BCL2 in complex with venetoclax (PDB: 6O0K) reveal that glycine 101 lies immediately adjacent to the indole ring system that extends into the P2 pocket. The backbone carbonyl of G101 participates in stabilizing the ligand's conformation through water-mediated hydrogen bonds, and the lack of a side chain permits close approach of the inhibitor's aromatic scaffold.

Molecular modeling of the G101V substitution shows that the valine methyl groups encroach on the venetoclax binding pose by approximately 1.5 to 2 Ångströms, generating unfavorable steric overlap. This clash cannot be relieved by minor ligand adjustments, as the indole-oxadiazole core is rigidly anchored by contacts deeper in the P2 and P4 pockets. The net result is destabilization of the bound state and rapid off-rate kinetics.

Docking venetoclax into wild-type versus G101V-mutant BCL2 models recapitulates these findings: binding scores drop significantly for the mutant, and visual inspection confirms the steric collision. Liganx Studio enables rapid setup of such mutation-aware docking experiments, allowing users to model the G101V substitution and evaluate alternative BH3 mimetics or next-generation scaffolds that might tolerate the valine side chain.

Clinical and Therapeutic Implications

BCL2 G101V has been detected in CLL patients progressing on venetoclax monotherapy and venetoclax-based combinations. Longitudinal sampling shows that the mutation is typically absent at baseline and emerges under selective pressure, often alongside other resistance mechanisms such as BCL2 amplification or upregulation of MCL1.

The presence of G101V poses a challenge for therapeutic sequencing. Because the mutation confers cross-resistance to structurally related BH3 mimetics that occupy the same P2 pocket, simply switching to another BCL2 inhibitor may not restore sensitivity. Rational approaches under investigation include dual BCL2/MCL1 inhibition, combination with BTK or PI3K inhibitors to reduce BCL2 dependence, and the development of next-generation BH3 mimetics with modified P2-binding motifs that circumvent the valine clash.

Preclinical efforts have explored analogs of venetoclax with smaller or more flexible substituents in the region that contacts G101. Early data suggest that certain modifications can partially restore binding to G101V-mutant BCL2, though potency against wild-type protein may be compromised. Balancing activity across mutant and wild-type forms remains a medicinal chemistry challenge.

Docking the BH3 Groove with Mutation Awareness

Mutation-aware docking is essential for evaluating resistance mutations like BCL2 G101V. Standard docking workflows that use only wild-type structures will overestimate the binding affinity of venetoclax and related compounds to resistant variants. Explicitly modeling the mutation—by mutating residue 101 from glycine to valine in the receptor structure—allows the docking engine to account for the introduced steric clash and report realistic binding modes and scores.

Our mutation docking guide provides step-by-step instructions for building mutant receptor models and validating docking poses. For BCL2 G101V, the workflow involves selecting a high-resolution BCL2 structure (such as PDB 6O0K), applying the G101V substitution, energy-minimizing the side chain, and re-docking venetoclax or candidate molecules. Comparing docking scores and binding modes between wild-type and G101V models immediately reveals the impact of the mutation and guides structure-based optimization.

Beyond venetoclax, mutation-aware docking enables exploration of how alternative BH3 mimetics—or entirely novel chemotypes—might evade G101V-mediated resistance. Screening compound libraries against both wild-type and mutant BCL2 can identify scaffolds that retain activity across both forms, prioritizing hits for experimental validation.

Outlook

BCL2 G101V exemplifies how solvent-front mutations at the ligand-binding interface can confer clinical resistance by introducing steric clashes that selectively disrupt inhibitor binding. Unlike gatekeeper or allosteric mutations, solvent-front substitutions directly alter the shape and chemistry of the binding pocket, requiring inhibitor redesign rather than simply optimizing contact points elsewhere.

As venetoclax continues to see widespread use in CLL, acute myeloid leukemia, and other BCL2-driven cancers, monitoring for G101V and related resistance mutations will be critical. Integrating mutation-aware docking into early-stage drug discovery campaigns can help anticipate resistance and guide the design of next-generation BH3 mimetics with broader mutant coverage.

References

• Blombery, P., Anderson, M. A., Gong, J. N., et al. (2019). Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discovery, 9(3), 342–353. DOI: 10.1158/2159-8290.CD-18-1119
• Souers, A. J., Leverson, J. D., Boghaert, E. R., et al. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine, 19(2), 202–208. DOI: 10.1038/nm.3048
• Birkinshaw, R. W., Gong, J. N., Luo, C. S., et al. (2019). Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nature Communications, 10(1), 2385. DOI: 10.1038/s41467-019-10363-1
• Tausch, E., Close, W., Dolnik, A., et al. (2019). Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica, 104(9), e434–e437. DOI: 10.3324/haematol.2019.222588